Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 4.1% – What’s Next?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares dropped 4.1% on Thursday . The stock traded as low as $4.22 and last traded at $4.25. Approximately 224,714 shares were traded during trading, a decline of 92% from the average daily volume of 2,834,480 shares. The stock had previously closed at $4.43.

Analyst Upgrades and Downgrades

IRWD has been the subject of a number of research reports. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Leerink Partners assumed coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a “market perform” rating and a $5.00 price target for the company. Finally, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $10.40.

Ironwood Pharmaceuticals Price Performance

The firm’s fifty day moving average is $4.01 and its two-hundred day moving average is $4.81. The firm has a market cap of $686.52 million, a price-to-earnings ratio of -143.00 and a beta of 0.41.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. During the same period in the previous year, the business posted $0.12 earnings per share. The business’s revenue for the quarter was down 19.4% compared to the same quarter last year. On average, equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Activity at Ironwood Pharmaceuticals

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares in the company, valued at $1,263,053.76. The trade was a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Rhumbline Advisers lifted its position in shares of Ironwood Pharmaceuticals by 0.7% in the second quarter. Rhumbline Advisers now owns 365,701 shares of the biotechnology company’s stock worth $2,384,000 after purchasing an additional 2,577 shares in the last quarter. KBC Group NV lifted its position in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,198 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Ironwood Pharmaceuticals by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 101,879 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 3,419 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Ironwood Pharmaceuticals by 10.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,831 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 4,016 shares during the last quarter. Finally, Creative Planning increased its stake in shares of Ironwood Pharmaceuticals by 12.7% in the third quarter. Creative Planning now owns 42,151 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 4,749 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.